Security key
09090D103
BiomX Inc. - Common Stock, par value $0.0001 per share (PHGE)
CUSIP: 09090D103
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 97,025
- Total 13F value
- $50,938
- Share change
- 0
- SEC-reported price per share
- $0.52
- Number of holders
- 2
- Shares outstanding
- 1,588,808
Holder snapshot
3 signals
Security identity
1 source field
Report period
Q3 2025
Institutions
2
Top holders
2
PHGE full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Previous quarter: Q2 2025
BiomX Inc. SEC filings
BiomX Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 09090D103
Recent filing periods:
Ownership snapshot
Top reported holders of PHGE - BiomX Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Cystic Fibrosis Foundation
Disclosed value leader
OrbiMed Israel BioFund GP...
Comparable rows
15/15
Latest evidence
30 Jun 2025
3/4/5
13D/G
13F
Lead comparable stake: 10%
13D/G row: Cystic Fibrosis Foundation
Showing 1-6 of 15 holder rows.
Quick read
Cystic Fibrosis Foundation leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
Cystic Fibrosis Foundation
10%
Nantahala Capital Management, LLC
10%
Centaurus Investments Ltd
7.6%
OrbiMed Israel BioFund GP Limited...
1%
DEERFIELD MANAGEMENT COMPANY, L.P.
163%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Cystic Fibrosis Foundation |
3/4/5
13D/G
10%+ Owner
|
10%
from 13D/G
|
$1,663,688
11,131,426 shares
mixed-class rows
|
— | 26 Feb 2025 |
| Nantahala Capital Management, LLC |
13D/G
13F
Company
|
10%
|
$1,496,518
2,494,197 shares
|
+$420,034 | 31 Mar 2025 |
| Centaurus Investments Ltd |
13D/G
Rodney Hodges
|
7.6%
|
$1,182,242
1,970,403 shares
|
$0 | 21 Apr 2025 |
| OrbiMed Israel BioFund GP Limited Partnership |
3/4/5
13D/G
10%+ Owner · ORBIMED ISRAEL GP LTD.
|
1%
from 13D/G
|
$5,250,517
13,777,980 shares
mixed-class rows
|
— | 15 May 2024 |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
Company
|
163%
|
$1,122,349
2,494,108 shares
|
— | 30 Jun 2025 |
| MORGAN STANLEY |
13F
Company
|
121%
|
$834,314
1,854,032 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
2
Shares
97,025
Rows available
2
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
2
Q3 2025 holders
2
Holder diff
0
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend